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Abstract
Autoimmune hepatitis (AIH) is a chronic necroinflammatory disease of the liver characterized by
hypergammaglobulinemia, characteristic autoantibodies, association with HLA DR3 or DR4 and a
favorable response to immunosuppressive treatment. The etiology is unknown. The detection of
non-organ and liver-related autoantibodies remains the hallmark for the diagnosis of the disease in
the absence of viral, metabolic, genetic, and toxic etiology of chronic hepatitis or hepatic injury. The
current classification of AIH and the several autoantibodies/target-autoantigens found in this
disease are reported. Current aspects on the significance of these markers in the differential
diagnosis and the study of pathogenesis of AIH are also stated. AIH is subdivided into two major
types; AIH type 1 (AIH-1) and type 2 (AIH-2). AIH-1 is characterized by the detection of smooth
muscle autoantibodies (SMA) and/or antinuclear antibodies (ANA). Determination of
antineutrophil cytoplasmic autoantibodies (ANCA), antibodies against the asialoglycoprotein
receptor (anti-ASGP-R) and antibodies against to soluble liver antigens or liver-pancreas (anti-SLA/
LP) may be useful for the identification of patients who are seronegative for ANA/SMA. AIH-2 is
characterized by the presence of specific autoantibodies against liver and kidney microsomal
antigens (anti-LKM type 1 or infrequently anti-LKM type 3) and/or autoantibodies against liver
cytosol 1 antigen (anti-LC1). Anti-LKM-1 and anti-LKM-3 autoantibodies are also detected in some
patients with chronic hepatitis C (HCV) and chronic hepatitis D (HDV). Cytochrome P450 2D6
(CYP2D6) has been documented as the major target-autoantigen of anti-LKM-1 autoantibodies in
both AIH-2 and HCV infection. Recent convincing data demonstrated the expression of CYP2D6
on the surface of hepatocytes suggesting a pathogenetic role of anti-LKM-1 autoantibodies for the
liver damage. Family 1 of UDP-glycuronosyltransferases has been identified as the target-
autoantigen of anti-LKM-3. For these reasons the distinction between AIH and chronic viral
hepatitis (especially of HCV) is of particular importance. Recently, the molecular target of anti-SLA/
LP and anti-LC1 autoantibodies were identified as a 50 kDa UGA-suppressor tRNA-associated
protein and a liver specific enzyme, the formiminotransferase cyclodeaminase, respectively. Anti-
ASGP-R and anti-LC1 autoantibodies appear to correlate closely with disease severity and
response to treatment suggesting a pathogenetic role of these autoantibodies for the hepatocellular
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injury. In general however, autoantibodies should not be used to monitor treatment, predict AIH
activity or outcome. Finally, the current aspects on a specific form of AIH that may develop in some
patients with a rare genetic syndrome, the autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome (APECED) are also given. Autoantibodies against liver
microsomes (anti-LM) are the specific autoantibodies detected in AIH as a disease component of
APECED but also in cases of dihydralazine-induced hepatitis. Cytochrome P450 1A2 has been
identified as the target-autoantigen of anti-LM autoantibodies in both APECED-related AIH and
dihydralazine-induced hepatitis. The latter may indicate that similar autoimmune pathogenetic
mechanisms can lead to liver injury in susceptible individuals irrespective of the primary defect.
Characterization of the autoantigen-autoantibody repertoire continues to be an attractive and
important tool to get access to the correct diagnosis and to gain insight into the as yet unresolved
mystery of how hepatic tolerance is given up and AIH ensues.
1. Introduction
Autoimmune hepatitis (AIH) is a rare chronic liver disease
of unknown etiology. The estimated prevalence of AIH in
Northern European countries is approximately 160–170
patients/106 inhabitants [1,2]. The disease predominates
among women and is characterized by hypergammaglob-
ulinemia even in the absence of cirrhosis, characteristic
autoantibodies, association with human leukocyte anti-
gens (HLA) DR3 or DR4 and a favorable response to
immunosuppressive treatment [3-5]. The onset of AIH
disease is usually insidious, with unspecific symptoms,
such as, fatigue, malaise, arthralgias, and fluctuating jaun-
dice, right upper quadrant pain or lethargy [5-8]. How-
ever, a substantial proportion of patients may have no
obvious signs or symptoms of liver disease, while occa-
sionally the presentation may be severe and almost iden-
tical to an acute or fulminant episode of viral hepatitis [5-
8]. Although AIH brings in mind the archetypal patient
being a young female with endocrine abnormalities, there
is nowadays increasing evidence that the disease can also
affect males and can present at almost any age (the large
majority of patients being between 50 and 70 years of age)
[6-12].
Liver histology is not pathognomonic for AIH and there is
no single serologic test of sufficient specificity for the diag-
nosis of AIH as for the diagnosis of viral hepatitis A to E.
Although the presence of autoantibodies is one of the dis-
tinguishing features of AIH, there is no single autoanti-
body with the diagnostic significance and specificity that
antimitochondrial autoantibodies (AMA) demonstrate
for the diagnosis of primary biliary cirrhosis (PBC). For
this reason, autoantibodies can not be employed as a sin-
gle marker for the diagnosis of AIH. It is rather a diagnosis
reached by the exclusion of other factors leading to
chronic hepatitis that include viral, toxic, genetic and met-
abolic causes [6]. Under this context, it is clear that some-
times AIH may be difficult to diagnose [7,8]. In 1992, the
International Autoimmune Hepatitis Group reported a
descriptive set of criteria that could be applied in the rou-
tine clinical practice for the diagnosis and classification of
patients as having either 'definite' or 'probable' AIH [13].
In addition, a diagnostic scoring system was devised to
provide an objective method for selection of relatively
homogeneous groups of patients for research purposes
[13]. The same group has remarkably simplified the
descriptive set of criteria and the diagnostic scoring system
in late 1998 (Tables 1 and 2) [6]. The diagnostic score
demonstrates that the presence of defined autoantibodies
is an integral part of the diagnosis of AIH but not its single
diagnostic tool [6,14].
In recent years however, significant progress has been
made in the characterization of liver-related target-
autoantigens. This has led to the notion that some of the
major target-autoantigens in AIH are active enzymes of
the human hepatic and non-hepatic microsomal xenobi-
otic metabolism [14-16]. The latter serve as a means to
investigate this still enigmatic liver disease. This article
will focus on the data that have evolved in the course of
the characterization of autoantibody-autoantigen "sys-
tem" in AIH by giving the current aspects on the role and
significance of this "system" in the differential diagnosis
and study of pathogenesis of AIH.
2. Classification of AIH
According to the pattern of autoantibodies detected in
AIH patients, a subclassification of the disease into three
types was proposed in 1994 [17]. AIH type 1 (AIH-1) is
characterized by the presence of antinuclear antibodies
(ANA) and/or smooth muscle autoantibodies (SMA)
which may associate with perinuclear anti-neutrophil
cytoplasmic antibodies (p-ANCA) [3,5,6,14,15]. AIH type
2 (AIH-2) is characterized by the detection of specific
autoantibodies against liver and kidney microsomal anti-
gens (anti-LKM type 1 or infrequently type 3) [14-16,18]
and/or antibodies against liver cytosol type 1 antigen
(anti-LC1) [14,15,19]. AIH type 3 (AIH-3) is characterized
by autoantibodies against soluble liver antigens (anti-
SLA) [20] or to liver-pancreas antigen (anti-LP) [21,22].Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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The serological diversity of autoantibodies found in AIH
supports the aforementioned subclassification and pro-
vides a framework for the scientific analysis of this heter-
ogeneous disease group [5,15]. It also demonstrates that
AIH may not be a single disease with a single underlying
mechanism but most likely is a group of diseases with a
similar clinical presentation [14,15]. This is further
substantiated by the finding of an unusual form of AIH in
10–18% of patients with a rare autosomal recessive disor-
der, the autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome (APECED) [23-25]. This
syndrome is characterized by chronic mucocuteneous
candidiasis, ectodermal dystrophy and autoimmune tis-
sue destruction particularly of the endocrine glands
(hypoparathyroidism, adrenocortical failure and gonadal
failure in females) [26-29].
However, due to recent clinical, serologic and genetic
findings, it has been suggested that anti-SLA seropositive
patients do not define a subgroup of AIH, but rather
belong to the AIH-1 group [30-32]. For this reason, subdi-
vision into AIH-1 (ANA, SMA, p-ANCA and/or anti-SLA/
LP positive) and AIH-2 (anti-LKM-1, anti-LKM-3 and/or
anti-LC1 positive) is in common usage (Table 3). Apart
from serological differences, AIH-2 seems to be clinically
and genetically distinguishable from AIH-1 [5,8,14].
Indeed, patients with AIH-2 are younger at presentation,
usually have higher levels of bilirubin and transaminases,
and are characterized by more severe disease than patients
with AIH-1 [5,6,14,18,33]. In addition, contrary to what
has been recorded in patients with AIH-1, no sustained
remission has been observed after the discontinuation of
immunosuppressive therapy in patients with AIH-2
[4,33]. Taking into consideration the genetic markers, it
has been found that the association between HLA DR3
and AIH-2 is rather weaker than that reported in AIH-1,
while an association between HLA DQ2 and AIH-2 has
been reported [14,18,33,34]. However, AIH-2 patients
represent only a small proportion of the total cases of AIH
[3-6]. In addition, the long-term outcome of the affected
patients appears to be similar both in AIH-1 and AIH-2
[6,33]. Therefore, the classification of AIH in these two
major subgroups is still uncertain and controversial
[6,8,13].
3. Detectable Autoantibodies in AIH-1
3.1. Anti-nuclear antibodies (ANA) and smooth muscle 
autontibodies (SMA)
ANA and/or SMA are almost exclusively requisites for the
diagnosis of AIH-1 [3,5,6,14,15,30]. In typical cases of
AIH-1, these autoantibodies are detected in significant tit-
ers (≥1;80 in adults and ≥1:40 in children) in almost half
of Caucasians patients with AIH-1, while ANA alone are
detected in 15% and SMA alone in 35% [5,30,35].
Table 1: Revised Scoring System for the Diagnosis of 
Autoimmune Hepatitis6.
Parameter/Features Score
Gender
- Female/Male +2/0
Degree of elevation above upper normal limit of 
ALP vs. aminotransferases
- <1.5 +2
- 1.5 – 3.0 0
- >3.0 -2
Total serum globulins, γ-globulins, or IgG above 
normal
- >2.0 +3
- 1.5 – 2.0 +2
- 1.0 – 1.5 +1
- <1.0 0
ANA, SMA or LKM-1 (titers by immunofluorescence 
on rodent tissues or HEp2-cells)
- >1 : 80 +3
- 1 : 80 +2
- 1 : 40 +1
- <1 : 40 0
- AMA positive -4
Hepatitis viral markers (IgM anti-HAV, HBsAg, IgM 
anti-HBc, anti-HCV and HCV-RNA)
- Positive/Negative -3/+3
Recent or current use of known or suspected 
hepatotoxic drugs
- Yes/No -4/+1
Average alcohol intake
- <25 g/day +2
- >60 g/day -2
Other autoimmune disease(s) in patient or first 
degree relatives
- Yes/No +2/0
Optional additional parameters (should be allocated 
only if ANA, SMA or LKM-1 are negative)
- HLA DR3, DR4, or other HLA with published association 
with AIH)
+1
- Seropositivity for any of ANCA, anti-LC1, anti-SLA/LP, 
anti-ASGPR and anti-sulfatide
+2
Liver histology
- Interface hepatitis +3
- Predominant lymphoplasmacytic infiltrate +1
- Rosetting of liver cells +1
- None of the above -5
- Biliary changes -3
- Other changes -3
Response to therapy (as defined in Table 2)
- Complete/Relapse +2/+3
Definite AIH if greater than 15 before treatment or greater than 17 
post-treatment; probable AIH if varies between 10–15 before 
treatment or 12–17 post-treatment. ALP: alkaline phospatase, IgM 
anti-HAV: hepatitis A virus IgM antibody, anti-HCV: hepatitis C virus 
antibody, HBsAg: surface antigen of hepatitis B virus, IgM anti-HBc: 
IgM antibody against the nuclear antigen of hepatitis B virus. Other 
abbreviations are the same as shown in the text.Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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The most frequent and conventional method for ANA
detection is the indirect immunofluorescence (IIF) assay
on cryostat sections of rodent tissues and HEp-2 cells
slides (Figures 1 and 2) [14,15,35,36]. Different patterns
of fluorescence are found by this assay due to the large var-
iability of target-autoantigens in the nuclei of HEp-2 cells
that have been recognized [35-40]. Actually, ANA are
found to be directed against single or double stranded
DNA, tRNA, SSA-Ro, snRNPs, laminins A and C, cyclin A
or histones [35-40]. Most commonly, a homogenous
(34–58%) or speckled (21–34%) immunofluoerescence
pattern is demonstrable [14,15,35-37]. So far however,
neither a liver-specific nuclear antigen nor a liver-disease-
specific ANA has been identified. For this reason, subtyp-
ing of ANA in cases of AIH-1 seems to have limited clinical
implication and diagnostic relevance in routine clinical
practice [6,14,15,35-40].
Table 2: Definitions of Response to Therapy.
Response Definition
Complete Either or both of the following: marked improvement of 
symptoms and return of serum AST or ALT, bilirubin and 
immunoglobulin values completely to normal within 1 year and 
sustained for at least a further 6 months on maintenance 
therapy, or liver biopsy specimen at some time during this 
period showing at most minimal activity.
or Either or both of the following: marked improvement of 
symptoms together with at least 50% improvement of all liver 
tests during the first month of treatment, with AST or ALT 
levels continuing to fall to less than twice the upper normal 
limit within 6 months during any reductions toward 
maintenance therapy, or a liver biopsy within 1 year showing 
only minimal activity.
Relapse Either or both of the following: an increased in serum AST or 
ALT levels of greater than twice the upper normal limit or a 
liver biopsy showing active disease, with or without 
reappearance of symptoms, after a "complete" response as 
defined above.
or Reappearance of symptoms of sufficient severity to require 
increased (or reintroduction of) immunosuppression, 
accompanied by any increase in serum AST or ALT levels, after 
a "complete" response as defined above.
AST: aspartate aminotransferase, ALT: alanine aminotransferase.
Table 3: Classification of Autoimmune Hepatitis (AIH) According 
to Autoantibodies Detection
Type of AIH Characteristic autoantibodies
AIH-1 ANA, SMA, p-ANCA anti-ASGP-R, anti-SLA/LP
AIH-2 anti-LKM-1, anti-LKM-3, anti-LC1, anti-ASGP-R
Abbreviations are the same as shown in the text.
High titer antinuclear antibodies (ANA) of the homogeneous  pattern by indirect immunofluoerescence on immobilized  HEp-2 cells in a female patient with autoimmune hepatitis  type 1 (AIH-1) Figure 1
High titer antinuclear antibodies (ANA) of the homogeneous 
pattern by indirect immunofluoerescence on immobilized 
HEp-2 cells in a female patient with autoimmune hepatitis 
type 1 (AIH-1). Homogeneous ANA are frequently found in 
AIH-1 (original magnification 40×).
Typical staining of antinuclear antibodies in the serum of a  patient with autoimmune hepatitis type 1 visualized by indi- rect immunofluoerescence on cryostat sections of rat liver  (original magnification 40×) Figure 2
Typical staining of antinuclear antibodies in the serum of a 
patient with autoimmune hepatitis type 1 visualized by indi-
rect immunofluoerescence on cryostat sections of rat liver 
(original magnification 40×).Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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SMA are detected by IIF on rodent liver and kidney, due to
staining of vessel walls (Fig. 3), and stomach due to stain-
ing of the muscle layer (Fig. 4). SMA are directed against
structures of the cytoskeleton such as actin, troponin,
vimentin and tropomyosin. In AIH-1, SMA are predomi-
nantly directed against F-actin [41]. The latter seems to be
diagnostically more relevant in pediatric patients where
SMA may be the only marker of AIH-1 even in titers as low
as of 1:40 [14,15]. Czaja et al [41] have suggested that
antibodies to actin are associated with a younger age of
disease onset, the presence of HLA-A1-B8-DR3 haplotype
and a greater frequency of treatment failure, death from
liver disease and earlier requirement for transplantation
than actin-antibody negative AIH-1 patients.
ANA and/or SMA – usually in low titers – may occur in
patients with chronic viral hepatitis B or C, but in most of
these cases SMA lack F-actin specificity [14,15,42,43].
From the clinical point of view, interferon-alpha adminis-
tration is generally safe in most cases of viral hepatitis
with ANA and/or SMA, although occasionally may pro-
voke mild self-limited autoimmune disorders compared
to viral hepatitis patients without ANA or SMA
autoantibodies [44-46]. During immunosuppressive
treatment, disappearance of ANA and/or SMA is observed
in the majority of patients with AIH-1 [47]. However,
autoantibody status is unable to predict immediate out-
come after cessation of corticosteroid administration.
Additionally, neither autoantibody titers at first diagnosis
nor autoantibody behaviour in the time course of the dis-
ease are prognostic markers for AIH-1 [14,15,47]. These
findings indicate that ANA and SMA are not involved in
the pathogenesis of AIH-1 and furthermore, their determi-
nation is more of diagnostic than prognostic value
[5,14,15,47].
3.2. Anti-neutrophil cytoplasmic autoantibodies (ANCA)
These autoantibodies are directed against cytoplasmic
constituents of neutrophil granulocytes and monocytes.
Classically, they are detected by IIF using ethanol-fixed
granulocytes as substrate [48]. Using the above method,
two major subtypes can be distinguished. ANCA showing
a diffuse or granular cytoplasmic staining (c-ANCA) and
ANCA characterized by a perinuclear-staining (p-ANCA).
Both c-ANCA and p-ANCA are valuable diagnostic and
prognostic markers in systemic vasculitides in particular
Wegener's granulomatosis and microscopic polyangiitis,
respectively [48,49]. Proteinase-3 has been identified as
the major target-autoantigen of c-ANCA in cases with
Wegener's granulomatosis, while myeloperoxidase is the
documented autoantigen of p-ANCA in most patients
with microscopic polyangiitis [48,49]. Since then, ANCA
(in most cases of p-ANCA type) were detected in a high
prevalence in other inflammatory disorders of unknown
aetiology such as, inflammatory bowel disease (more fre-
quently in ulcerative colitis than in Crohn's disease)
[50,51] and primary sclerosing cholangitis (PSC), a liver
disease that is frequently associated with ulcerative colitis
[51,52].
Several recent studies however, have also documented the
presence of high titers of p-ANCA in the sera of patients
with AIH-1 (Fig. 5; prevalence range 40–96%) [53-58]
Smooth muscle antibodies by indirect immunofluoerescence  on rat kidney (from a female patient with autoimmune hepa- titis type 1) Figure 3
Smooth muscle antibodies by indirect immunofluoerescence 
on rat kidney (from a female patient with autoimmune hepa-
titis type 1). The immunofluorescence involves smooth mus-
cle fibers within blood vessels (original magnification 40×).
Smooth muscle autoantibodies by indirect immunofluoeres- cence on rat stomach (serum from a female patient with  autoimmune hepatitis type 1) Figure 4
Smooth muscle autoantibodies by indirect immunofluoeres-
cence on rat stomach (serum from a female patient with 
autoimmune hepatitis type 1). The immunofluorescence 
involves smooth muscle fibers within muscularis mucosa 
(original magnification 40×).Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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and to a much lesser extent in PBC patients (prevalence
range 0–39%) [54,58,59]. Occasionally, high titers of c-
ANCA can be detected in AIH-1 (Dalekos GN, 2002,
unpublished observations). In contrast, p-ANCA have not
been detected in serum samples from patients with AIH-2
[57]. Low ANCA titers are detected infrequently in
patients with alcoholic or chronic viral liver diseases
[54,57,60]. However, a recent large study in 516 patients
with hepatitis C virus (HCV) infection revealed the
presence of ANCA in as high as 55.6% of patients [61].
Interestingly these investigators have shown that all HCV
positive sera with ANCA had c-ANCA pattern on IIF and
contained proteinase-3 specificity [61]. The clinical rele-
vance of this finding remains to be determined. In
patients with AIH-1, PBC or PSC the detection of ANCA
appears to be associated with a more severe disease course
or the presence of cirrhosis [54,62]. The latter suggestion
however, was not confirmed by more recent studies
[53,54].
To determine the antigenic specificities of ANCA, antigen-
specific enzyme linked immunosorbent assays (ELISAs)
and Western blotting followed by immunodetection can
be performed [14,63]. Using these techniques it became
obvious that in AIH-1 the target-autoantigens recognized
are multiple including cathepsin G, catalase, alpha-eno-
lase, lactoferrin, actin and high mobility group (HMG)
non-histone chromosomal proteins HMG1 and HMG2
[14,54,56,58,62-65]. However, the determination of anti-
genic specificities of ANCA seems to have limited clinical
relevance in patients with AIH-1 [14,15,54,56].
In conclusion, the detection of ANCA may be a useful
additional marker in searching for AIH-1, in particular in
ANA/SMA/anti-LKM-1 negative cases of AIH. With the
exception of a recent paper by Wu et al [61] the detection
of ANCA is rather rare in chronic viral hepatitis
[14,54,57,60]. The latter may prove useful in the differen-
tial diagnosis between patients with AIH and those with
viral hepatitis who tested positive for ANA or SMA. Fur-
thermore, since ANCA appear to be relatively rare in PBC
[54,59], these autoantibodies may prove useful for distin-
guishing between genuine cases of AIH and cases of PBC
with features overlapping with those of AIH [6]. However,
due to the lack of specificity for the diagnosis of AIH and
to its obscure role – if any – in AIH, their routine determi-
nation is not recommended [14,15].
3.3. Autoantibodies against the asialoglycoprotein 
receptor (anti-ASGP-R)
The asialoglycoprotein receptor (ASGP-R) is a liver-spe-
cific glycoprotein of the cell membrane. Its main function
is the internalization of asialoglycoproteins by binding a
terminal galactose residue to coated pits. Anti-ASGP-R
autoantibodies are detected in 88% of patients with AIH
(both types) [66,67]. However, these autoantibodies are
also found in some patients with PBC, chronic viral
hepatitis B and C and alcoholic liver disease although at
lower frequency and lower titers [14,15,66,67].
The ASGP-R is preferentially expressed on the surface of
periportal liver cells where piecemeal necrosis is found as
a marker of severe inflammatory activity in patients with
AIH [68]. This finding may suggest a possible immun-
opathogenetic involvement of anti-ASGP-R autoantibod-
ies in AIH [69]. The general presumption is that target of
potentially tissue-damaging autoreactions in AIH must be
liver-specific and available to the immune system in vivo
(e.g. expression on the surface of hepatocytes). So far,
ASGP-R is the only target-autoantigen that has been posi-
tively identified and fulfils these criteria [68,69].
Additional support to this emerged from the determina-
tions of anti-ASGPR autoantibodies in consecutive AIH
patients. The levels of anti-ASGP-R autoantibodies vary
according to the inflammatory activity of the disease. In
addition, anti-ASGP-R antibody titers decreased signifi-
cantly in response to immunosuppression, while they
reappear when the disease has relapsed [66,70]. These
autoantibodies may be diagnostically helpful when other
autoantibodies are not detected and AIH is suspected.
However, due to the belief that anti-ASGPR antibody rep-
resents a general marker of liver autoimmunity and the
limitations in its detection (requires chemically purified
ASGP-R, which is not yet widely available), its routine use
is not generally recommended.
Perinuclear staining of anti-neutrophil cytoplasmic autoanti- bodies (p-ANCA) by indirect immunofluoerescence on etha- nol fixed human granulocytes (serum from an ANA negative  patient with autoimmune hepatitis type 1) Figure 5
Perinuclear staining of anti-neutrophil cytoplasmic autoanti-
bodies (p-ANCA) by indirect immunofluoerescence on etha-
nol fixed human granulocytes (serum from an ANA negative 
patient with autoimmune hepatitis type 1). Original magnifi-
cation 40×).Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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3.4. Antibodies against soluble liver antigens (anti-SLA) or 
to liver-pancreas antigen (anti-LP)
The anti-SLA autoantibodies were described for the first
time in 1987 [20]. They cannot be detected by IIF on com-
mon substrate. A competitive ELISA or a radioimmu-
noassay usually detects these autoantibodies [20,32,71].
SLA is found in 100000 g supernatant of liver homoge-
nate and represent a cytosolic protein which is neither
organ nor species specific [72]. However, the highest con-
centrations are found in liver and kidney tissues. The anti-
SLA autoantibodies are detected in patients with AIH
alone or in combination with SMA and/or ANA [30-
32,73]. As noted above, similarities in the clinical profile
between patients with AIH-1 (ANA and/or SMA positive)
and AIH patients with anti-SLA alone in addition with an
approximately 30% seropositivity overlap between anti-
SLA and SMA and/or ANA suggest that anti-SLA is rather
an additional important marker for the diagnosis of AIH-
1, than a marker of a third type of AIH [6,14,30-32].
A scientific group from Tuebingen, Germany described for
the first time the anti-LP autoantibodies in 1981 [21]. The
LP antigen was predominantly detected in the S100 super-
natant of liver and pancreas homogenates, indicating that
this antigen was a soluble protein. Until recently, anti-LP
and anti-SLA autoantibodies were thought to be different
[20-22]. However, Wies et al report [74] provides convinc-
ing evidence and confirms previous suggestions that anti-
SLA and anti-LP are one and the same autoantibody (anti-
SLA/LP). In addition, the same study demonstrated that
the identified target-autoantigen of anti-SLA/LP
autoantibodies (a 35–50 kDa protein) was neither cytok-
eratins 8 or 18 [71] nor glutathione-S-transferase isoen-
zyme [75]. The results from two independent groups
[76,77] were similar with those found by Wies et al [74].
After screening of cDNA expression libraries they identi-
fied a previously unknown amino acid sequence, which
presumably encodes a UGA-suppressor tRNA-associated
protein, as the targen-autoantigen of anti-SLA/LP autoan-
tibodies [76,77]. The UGA-suppressor serine tRNA-pro-
tein complex is likely to be involved in cotranslational
selenocysteine incorporation in human cells [78]. It was
then obvious that the identification of SLA/LP autoanti-
gen would allow the establishment of a reliable, univer-
sally available diagnostic test for AIH but also it would
provoke the investigation in the area of autoimmune liver
diseases.
Regarding disease specificity, anti-SLA/LP autoantibodies
have not been detected in patients with AIH-2, PBC, PSC,
chronic viral hepatitis, alcoholic liver disease and non-
hepatic autoimmune diseases by standardized ELISAs
using reference autoantibody or recombinant antigen
[20,32,73,79]. Ballot et al [32] also showed that these
autoantibodies are different from anti-LC1. For these rea-
sons, anti-SLA/LP has been considered as a valuable and
specific diagnostic marker of AIH [31,32,73,74,76,77,79].
However, a recent study from the United Kingdom [80]
has shown that anti-SLA/LP autoantibodies can also be
detected in AIH-2 and in children with PSC. These inves-
tigators used eukaryotically expressed tRNP ((Ser) Sec)/
SLA as target in a radioligand assay (RLA) which is well
known as a more sensitive test than ELISAs and immuno-
blot due to its ability to identify antibodies directed to
conformational epitopes [81-83]. Their novel findings
need confirmation from other research groups and partic-
ularly to address whether anti-SLA/LP reactivity is also
present in adult PSC. Recent data confirmed the previous
finding that patients with anti-SLA/LP display a more
severe course of AIH [79,80,84]. The latter suggest that
anti-SLA/LP may be linked to the pathogenesis of the
autoimmune process although the exact function and its
role in autoimmunity are so far unclear [14,15]. From the
clinical point of view however, this autoantibody may be
helpful in an attempt to reduce the group of cryptogenic
hepatitis and/or cirrhosis.
4. Detectable Autoantibodies in AIH-2
4.1. Autoantibodies against liver-kidney microsomes (anti-
LKM)
Three types of anti-LKM autoantibodies have been identi-
fied [3,5,14,15,18,30,63,72,85]. The LKM type 1
autoantibody (anti-LKM-1) is the characteristic serologic
marker for the diagnosis of AIH-2 [5,18,63,72]. These
autoantibodies were first described by Rizzetto et al [86],
using the IIF method on rodent liver and kidney sections.
The characteristic features of anti-LKM-1 autoantibodies
are the diffuse staining of cytoplasm of the entire liver lob-
ule and the exclusive staining of the P3 portion of the
proximal renal tubules (Fig. 6) [18]. Due to this staining
pattern of kidney sections anti-LKM-1 can be easily distin-
guished from AMA, which stain proximal and distal renal
tubules (Fig. 7). Western blots with hepatic and renal
microsomes revealed a protein band at 50 kDa
[5,14,15,63,72,87].
The major target-autoantigen of anti-LKM-1 autoantibod-
ies in AIH-2 has been identified as the cytochrome P450
2D6 (CYP2D6) [87-89]. It has been shown that anti-LKM-
1 autoantibodies inhibit the enzymatic activity of
CYP2D6 in vitro, but not in vivo [90]. Epitope mapping
experiments of CYP2D6 autoantigen have defined at least
four different linear epitopes [91,92]. The most immuno-
dominant epitopes of CYP2D6 were amino acids 257–
269 and 321–351, which are recognized in about 70%
and 50% of AIH-2 cases, respectively [91,92]. Two infre-
quent epitopes consisting of amino acids 373–389 and
410–429 are also recognized by anti-LKM-1 in some cases
[92]. Recently, Klein et al [93] and Kerkar et al [94]
reported another immunodominant epitope of CYP2D6Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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(amino acids 193–212) recognized in about 70% and 93
% of AIH-2 patients, respectively. However, due to failure
of inhibition of CYP2D6 enzymatic activity using epitope
specific antibodies and since the absorption of the above
linear epitopes was unable to absorb inhibitory anti-
CYP2D6 autoantibodies, the existence of additional
conformational epitopes on CYP2D6 autoantigen has
been postulated [95].
It is noteworthy to state here that depending on the geo-
graphic origin, 0–7% of patients with chronic hepatitis C
– irrespective of the HCV genotype – develop anti-LKM-1
autoantibodies [6,14,43,63,96,97]. Recently, two studies
have shown a higher prevalence of anti-LKM autoantibod-
ies (up to 10%) in a small number of children or adult
patients with HCV infection [98,99]. As stated for AIH-2,
CYP2D6 is the major target autoantigen recognized by
anti-LKM-1 autoantibodies in HCV patients [14,15,81-
83,88,92-96]. However, we and others have failed to
document CYP2D6 as the major target autoantigen of
anti-LKM antibodies in HCV/anti-LKM positive sera
[98,99]. In addition, recently Miyakawa et al [100] identi-
fied CYP2E1 and CYP3A4 as target autoantigens of anti-
LKM autoantibodies in two patients with anti-LKM-posi-
tive chronic hepatitis C. Taking together, these findings
may further indicate the heterogeneous autoimmune
reactions that might take place in anti-LKM positive
patients with chronic hepatitis C.
The antigenic sites on CYP2D6 autoantigen recognized by
anti-LKM-1 autoantibodies are different in AIH-2 and
HCV/anti-LKM-1 positive cases [92-95,101-104]. For
example, the major linear epitope of 257–269 amino
acids, as well as the newly reported peptide of 193–212
amino acids are recognized in 70–93% of AIH-2 patients
but only in 18–50% of HCV/anti-LKM-1 positive patients
[83,93,94,101]. Additional support to the presence of
conformation-dependent anti-LKM-1 autoantibodies in
HCV/anti-LKM-1 positive serum samples has emerged
from previous studies [99,102,105]. In the latter studies
only about 30% of HCV/anti-LKM-1 positive sera reacted
with 50 kDa component using Western blot assays, while
additional bands at 59 kDa, 70 kDa and 80 kDa were
detected [99,102,105]. However, even taking into account
the above additional bands, no more than 45% of all sera
tested reactive by Western blot. In contrast, a significant
proportion of the previous negative sera tested positive for
anti-LKM-1 using a specific competitive ELISA, while
denaturation of the antigens prior to perform the ELISA
resulted in complete loss of the signal [105].
Recently, the development of a more sensitive and specific
assay for the detection of anti-LKM-1 autoantibodies was
achieved [14,15]. This novel assay is a quantitative RLA
based on immunoprecipitation using 35S-methionine-
labelled CYP2D6 antigen obtained by in vitro transcrip-
tion and translation synthesis [81-83,99,104]. Using this
assay it was shown that the anti-LKM-1 titers do not differ
significantly between AIH-2 and HCV/anti-LKM-1 posi-
tive patients [81-83]. The presence of anti-LKM-1 in some
patients with HCV infection led to the proposal for a fur-
Antibodies against liver-kidney microsomes type 1 (anti- LKM-1) react to the proximal tubules of the rat kidney Figure 6
Antibodies against liver-kidney microsomes type 1 (anti-
LKM-1) react to the proximal tubules of the rat kidney. The 
absence of reactivity against thedistal tubules of the rat kid-
ney (see also Fig. 6B) and parietal cells of the rat stomach dis-
tinguishes anti-LKM-1 autoantibodies from antimitochondrial 
antibodies (original magnification 40×).
Antimitochondrial antibodies react to the proximal and distal  tubules of the rat kidney (original magnification 40×) Figure 7
Antimitochondrial antibodies react to the proximal and distal 
tubules of the rat kidney (original magnification 40 ×). In 
these cases there is also reactivity to the parietal cells of the 
rat stomach.Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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ther division of AIH-2 into AIH-2a (younger, predomi-
nantly female patients without evidence of HCV
infection) and AIH-2b (older, predominantly male
patients with HCV infection) [13,106]. Nowadays how-
ever, after the marked improvements in the reliability and
availability of tests for HCV detection such a subdivision
of AIH-2 appears unreasonable and tends to be deleted.
Actually, HCV/anti-LKM-1 positive patients represent
cases of "true" HCV infection with autoimmune features
[6,107].
From the clinical point of view, screening for anti-LKM
autoantibodies is recommended before the initiation of
interferon-alpha therapy in HCV patients and if found
positive a careful monitoring appears reasonable because
occasionally interferon-alpha may unmask, or provoke
autoimmune hepatic reactions and even "true"AIH
[6,43,104,108-110]. Dalekos et al [104] studied antibody
titers and performed epitope mapping of LKM-1-positive
sera from patients with chronic hepatitis C. Interestingly,
a patient with a high LKM-1 titer and autoantibodies
directed against an epitope of amino acids 257–269,
which are preferentially recognized by patients with AIH-
2, showed exacerbation of the disease under interferon-
alpha treatment. In contrast to other patients with HCV
infection, this patient further recognized a rarely detected
epitope on the C-terminal third of the protein. These
results suggest that determination and monitoring of
CYP2D6 autoantibody titers by both IIF and the RLA in
combination with epitope mapping of CYP2D6 in HCV/
anti-LKM positive patients before the initiation of
interferon-alpha treatment, might be helpful in an
attempt to identify those patients at risk of developing
undesired autoimmune reactions [104].
The mechanism(s) of the development and the patho-
genic role of anti-LKM-1 autoantibodies in hepatocellular
injury are still unclear. It has been suggested that viral
infections by herpes simplex virus (HSV) and related
viruses may trigger the autoantibody formation through
molecular mimicry in at least some individuals with AIH-
2 [91]. Manns et al [91] tested 26 LKM-positive sera using
Western blot with partial sequences of recombinant
CYP2D6. Eleven sera recognized a short minimal epitope
of eight amino acids with the sequence DPAQPPRD.
Twelve other clones recognized a larger epitope contain-
ing this eight-amino acid core sequence. The search of
electronic databases revealed an interesting match of the
minimal epitope with the primary structure of the
immediate early protein IE 175 of HSV-1 now known as
infected cell protein 4 (ICP4) of HSV-1 (Fig. 8). Sequence
identity was present for the PAQPPR sequence. This
hypothesis was further supported by a case study in a pair
of identical twins [111]. In this study, one sister suffered
from AIH-2 but the other one was healthy. Interestingly,
only the sister suffering from AIH-2 was HSV positive, and
her serum recognized the viral protein ICP4 in lysates of
HSV-infected cells [111]. So far however, overall evidence
for mimicry as a driving force of AIH is not convincing.
Besides molecular mimicry, chemical modification of self-
proteins and/or immunological cross-reactivity to homol-
ogous autoantigens may also provide potential triggers for
autoimmune responses. The latter has been suggested by
Choudhuri et al [112] who have shown that in AIH-2
patients the linear epitope 321–351 of CYP2D6 cross
reacts with amino acids 33–51 of carboxypeptidase-H
(the target autoantigen of islet cell autoantibodies in insu-
lin dependent diabetes mellitus), as well as, with amino
acids 307–325 of 21-hydroxylase (major target autoanti-
gen in Addison's disease). These findings possibly indicate
the presence of a common motif of CYP2D6, carbox-
ypeptidase-H and 21-hydroxylase, which may contribute
through a cross reactive immune response to the develop-
ment of multiple endocrinopathies in the course of AIH-
2. Additional support to this hypothesis emerged from
two recent studies by Kerkar et al [94] and Bogdanos et al
[113]. In the first study the authors were able to show the
similarity and cross-reactivity between the immunodomi-
nant epitope 193–212 of CYP2D6 and homologues of
two unrelated viruses (HCV 2977–2996 and CMV 121–
140) [94]. In the second study the researchers investigated
whether the immunodominant epitope 252–271 of
CYP2D6 in anti-LKM-1 positive AIH-2 and homologues
from the NS5B and E1 proteins of the HCV polyprotein
and the ICP4 of HSV-1 are targets of humoral immune
response in anti-LKM-1 positive and anti-LKM-1 negative
HCV infected patients and furthermore whether this
response is cross-reactive [113]. The hypothesis of molec-
ular mimicry and cross-reactivity in LKM-1 production
has not been addressed experimentally. The authors for
the first time gave experimental support to the notion that
molecular similarity between CYP2D6, HCV and HSV can
result in LKM-1 production via a cross-reactive response in
genetically susceptible individuals (interestingly only the
HCV positive/LKM-1 positive patients with viral/self
cross-reactivity possessed the HLA B51 allotype) [113].
Taking together, the above studies suggest that multiple
exposure to viruses mimicking self may represent an
important pathway to the development of autoimmunity
[94,113].
Two possible mechanisms have been proposed for the
involvement of anti-LKM-1 autoantibodies in the patho-
genesis of liver injury. The first appears to be a direct bind-
ing of these autoantibodies to hepatocytes, leading to lysis
of liver cells, while the second is associated with an anti-
LKM-1 induction of activating liver-infiltrating T lym-
phocytes, which indicates the combination of B and T cell
activity in the autoimmune process involved [114-117]. AJournal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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prerequisite for both anti-LKM-1 production and the acti-
vation of pathogenetic mechanisms involved in liver
injury, is the expression of CYP2D6 on the surface of the
patients' hepatocytes. Under this context, Ma et al [118]
showed that key residues of a major CYP2D6 epitope
(316–327) are exposed on the surface of the molecule and
may represent key targets for anti-CYP2D6 production. In
addition, recent data provides convincing evidence that
anti-LKM-1 autoantibodies recognize CYP2D6 exposed
on the plasma membrane of hepatocytes from either AIH-
2 or HCV/anti-LKM-1 positive patients [114,115] suggest-
ing a pathogenetic role for these autoantibodies in hepatic
tissue damage either in AIH-2 or in some cases of HCV/
anti-LKM-1 positive patients [104,109,110,115].
So far, anti-LKM type 2 autoantibodies (anti-LKM-2) have
been detected only in some cases of drug-induced hepati-
tis caused by tienilic acid [14,63]. The target autoantigen
of anti-LKM-2 has been documented as the CYP2C9 [85].
A proposed mechanism for the induction of anti-LKM-2
could be the binding of an active metabolite of the drug
to the CYP2C9 protein, which then becomes antigenic
[14,63,72,85].
Anti-LKM type 3 autoantibodies (anti-LKM-3) alone or in
combination with anti-LKM-1 are also detected in about
5–10% of patients with AIH-2 [16,119]. In contrast to
anti-LKM-1 and anti-LKM-2 autoantibodies, which on
immunofluorescence stain liver and kidney tissues only,
with anti-LKM-3 additional fluorescence signals may be
present with tissue from the pancreas, adrenal gland,
thyroid, and stomach. Family 1 of UDP-glycuronosyl-
transferases (UGT1) is the main target autoantigen of anti-
LKM-3 autoantibodies (molecular weight of 55 kDa)
Linear B-cell epitopes on cytochrome P450 2D6 in autoimmune hepatitis type 2 Figure 8
Linear B-cell epitopes on cytochrome P450 2D6 in autoimmune hepatitis type 2. The immunodominant epitope 257–269 aa 
shares sequence homology with the immediate early protein IE 175, a transcription factor of herpes simplex virus type 1 (now 
known as infected cell protein 4 or ICP4). Although this is an attractive model for the hypothesis of molecular mimicry, overall 
evidence for mimicry as a driving force of autoimmune hepatitis is not convincing.Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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[119,120]. These autoantibodies were first described in
about 13% of patients with chronic hepatitis D, but not in
patients with chronic hepatitis B or C [121]. However,
three recent reports have shown the presence of anti-LKM-
3 autoantibodies in some patients with HCV infection
[99,122,123]. These findings may further support the
heterogeneous phenomenon of the HCV-induced
autoimmunity.
4.2. Autoantibodies against liver cytosolic protein type 1 
(anti-LC1)
In 1988 a second autoantibody marker of AIH-2 was rec-
ognized [19]. This autoantibody was found to react to a
liver cytosolic protein. The autoantibody is organ specific
but not species specific and was therefore called anti-LC1
[19]. The anti-LC1 autoantibodies are characterized by a
cytoplasmic staining of the periportal hepatocytes when
the IIF assay is used for their detection. The hepatocellular
layer around the central veins is not stained [19,124].
These findings indicate that the target autoantigen of anti-
LC1 autoantibodies is not uniformly distributed in rodent
liver tissues. They are detected in about 30% of patients
with AIH-2 [19,124] and in approximately 50% of all
anti-LKM-1 positive cases [125]. It is noteworthy that the
anti-LC1 autoantibodies proved to be the only serological
marker in 10% of patients with AIH [19].
The detection of anti-LC1 autoantibodies by IIF is
obscured due to the anti-LKM-1 pattern that frequently
found in most of the anti-LC1 positive sera. For these rea-
sons other techniques such as, the ouchterlony double
diffusion, immunoblot or counter-immunoelectrophore-
sis are required for their detection [19,124-126]. By
immunoblotting, anti-LC1 positive serum samples recog-
nize a liver specific cytosolic protein of 58–62 kDa [124-
126]. Recently the molecular target of anti-LC1 was iden-
tified as the formiminotransferase cyclodeaminase
(FTCD) [127], which is a polymeric bifunctional enzyme
involved in folate metabolism. However, another group
demonstrated the arginninosuccinate lyase (ASL) as the
target autoantigen of a weak precipitin line detected by the
ouchterlony double diffusion assay in patients with
autoimmune or viral hepatitis [128].
Anti-LC1 autoantibodies have been proposed as a more
specific marker of AIH-2 than anti-LKM-1 autoantibodies,
since in the original reports their presence was never asso-
ciated with HCV infection [19,124]. However, a recent
study by Lenzi et al [125] confirmed the above aspect only
in the pediatric subset of their patients, while a substantial
proportion of the adults with anti-LC1 autoantibodies
had also markers of HCV infection. The significance of the
association between anti-LC1 autoantibodies and HCV
infection remains uncertain and has to be established
[106,129]. In contrast to what has been found for anti-
LKM-1, the titers of anti-LC1 autoantibodies appear to
parallel with disease activity [130]. The latter may indicate
a possible involvement of anti-LC1 in the pathogenesis of
AIH-2. However, the clinical significance of anti-LC1 is
not yet completely defined.
5. Detectable Autoantibodies in AIH in APECED
Chronic hepatitis as a disease component of APECED may
develop in 10–18% of patients [14,15,23-25,28,29,63].
APECED appears to be caused by mutations in a recently
identified gene, the autoimmune regulator gene (AIRE),
and represents the only known autoimmune disease with
a monogenetic mutation today [26,27,131]. It is interest-
ing that patients with AIH in the absence of APECED do
not display mutations of the AIRE gene and are therefore
genetically distinct from patients with AIH as a compo-
nent of APECED [132].
Similar to AIH-2, hepatitis in APECED is associated with
autoantibodies directed against cytochrome P450 pro-
teins. In a large study with APECED patients, a typical
LKM staining pattern and a predominant staining of the
perivenous hepatocytes in the absence of staining of the
kidney were observed [23]. The latter pattern is due to
autoantibodies called liver microsomal autoantibodies
(anti-LM). In this study each of anti-LKM and anti-LM
antibodies were found in 8% of the patients [23]. These
findings indicate that two or more different microsomal
antigens are hepatic target-autoantigens in APECED.
Indeed, screening of APECED sera with recombinant anti-
gens using Western blots has shown reactivity against four
different hepatic cytochromes P450: CYP1A1, CYP1A2,
CYP2A6 and CYP2B6 [23-25,133]. CYP1A1, CYP2A6 and
CYP2B6 are expressed both in liver and in kidney result-
ing to an LKM staining pattern, while CYP1A2 is not
expressed in the kidney leading to the LM staining.
Among the four autoantibodies anti-CYP2A6 were
detected with the highest prevalence in a Finnish APECED
patients group (15.6%), while anti-CYP1A2 were found in
6.3% [23]. These results were confirmed by quantitative
immunoprecipitation assays with recombinant 35S-
labeled CYP1A2 and CYP2A6.
Contrary to a previous work in Sardinian patients with
APECED [25], the detection of anti-CYP2A6 autoantibod-
ies in a larger group of Finnish patients was not associated
with the presence or absence of hepatitis, while anti-
CYP1A2 autoantibodies were detected only in APECED
patients with hepatitis [23]. These findings indicate that
anti-CYP1A2 is a specific marker for AIH as a component
of APECED, albeit with a low sensitivity [23,24]. Anti-
CYP2A6 autoantibodies may be used as an indicator for
APECED, if they are present in a patient with AIH. In par-
allel with the above conclusions is the anti-LKM/LMJournal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
Page 12 of 17
(page number not for citation purposes)
detection by IIF in about 50% of patients with AIH as part
of the APECED and in only 11% of APECED patients
without hepatitis [23]. The same study showed that the
prevalence of ANA detection in APECED patients was
high (22%) but irrespective of the presence or absence of
hepatitis. Therefore ANA are not useful laboratory mark-
ers for AIH in APECED [23]. To the contrary, none of the
patients' sera tested positive for anti-SLA, anti-CYP2D6 or
anti-FTCD autoantibodies, which are specific markers of
AIH-1 and AIH-2 [23]. On the other hand, CYP1A2 and
CYP2A6 could not be identified as hepatic autoantigens in
the disease control groups consisting of patients with idi-
opathic AIH or patients with autoimmune rheumatic dis-
eases [23]. These findings indicate that idiopathic AIH
and AIH in APECED are characterized by different molec-
ular targets of autoimmunity, which do not overlap.
Therefore, AIH and hepatitis as part of the APECED may
be distinguished on the basis of differences in autoanti-
body profile (Tables 4 and 5).
Dalekos et al [134] using the sensitive quantitative RLA
reported for the first time the presence of anti-CYP2A6
autoantibodies in about 2% of HCV-positive sera in gen-
eral and in 7.5% of LKM-1-positive/HCV-positive sera.
The latter further supports the low specificity of this
autoantibody as a marker for AIH in APECED.
Interestingly, anti-CYP2A6 autoantibodies were not
detected in patients with AIH-2 who exhibit high titers of
anti-LKM-1 autoantibodies [134]. The clinical relevance
of this finding in HCV infection remains to be
determined.
Anti-LM autoantibodies are first described in dihydrala-
zine-induced hepatitis [135]. The major target autoanti-
gen of anti-LM in both conditions (hepatitis as part of the
APECED and drug-induced hepatitis) has been docu-
mented as the CYP1A2 [23-25,133,135]. In cases of dihy-
dralazine-induced hepatitis the production of anti-LM
autoantibodies has been attributed to adduct formation
of CYP1A2 with an activated metabolite of the drug [136].
By contrast, in APECED patients no relationship between
CYP1A2 and drug usage is known. In addition, it is not
known whether in APECED patients a close monitoring of
anti-LM may lead to early, or even prophylactic, treatment
of hepatitis as a new disease component. Evidence that
autoantibodies may be found before the clinical and/or
laboratory manifestation of a new disease component in
APECED comes from adrenal and ovarian insufficiencies,
where the respective autoantibodies are detected 2–3
years before the clinical presentation of the autoimmune
components [137].
Another hepatic autoantigen in APECED, the aromatic-L-
amino acid decarboxylase (AADC) has also been identi-
fied recently [133,138]. This enzyme is expressed in the
liver cytosol and was originally described as a β-cell
autoantigen [133]. The prevalence of anti-AADC autoan-
tibodies is significantly increased in APECED patients
with vitiligo (88%) and hepatitis (92%) [5,14,29]. So far,
anti-AADC autoantibodies have only been reported in
APECED and their role in AIH and vitiligo as disease com-
ponents of APECED deserve further investigation.
Table 4: Detectable autoantibodies in AIH-1, AIH-2 and AIH as part of APECED
AIH-1 or AIH-2 AIH in APECED
ANA, SMA, ANCA, anti-ASGP-R anti-SLA/LP (molecular target: UGA 
suppressor tRNA-associated protein), anti-LKM-1 (molecular target: 
CYP2D6), anti-LKM-3 (molecular target: UGT1), anti-LC1 (molecular 
target: FTCD)
ANA, anti-LC (molecular target: unknown), anti-LKM (molecular 
targets: CYP2A6, CYP1A1 and CYP2B6), anti-LM (specific autoantibody; 
molecular target: CYP1A2)
Abbreviations are the same as shown in the text.
Table 5: Differential diagnosis of chronic liver diseases according to the presence or absence of autoantibodies against molecularly 
defined autoantigens of cytochrome P450 complex using the radioligand assay.
Anti-CYP2D6 Anti-CYP2A6 Anti-CYP1A2 Chronic liver disease
+ - - AIH-2 (94–100%), HCV (0–10%)
- + - HCV, APECED with or without hepatitis
- - + AIH in APECED, drug induced hepatitis
++- H C V  ( 0 – 7 % )
- + + AIH in APECED
Abbreviations are the same as shown in the text.Journal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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6. Concluding Remarks
In clinical practice the recognition of AIH is of great
importance since most of the patients respond favorably
to antiinflammatory and immunosuppressive treatment.
In addition, recent novel findings dealing with the bone
marrow hemopoietic progenitor cells and bone marrow
stromal cells of patients with AIH suggests alternative
therapeutic options even in refractory cases [139].
Diagnostic criteria for this disease have been codified
recently [6]. These include descriptive criteria and scoring
system based on clinical, serologic and histologic features
of AIH (Table 1), which contribute substantially to the
differential diagnosis of the disease from other forms of
chronic hepatitis associated with autoimmune phenom-
ena (Table 6). The discrimination between AIH and HCV
infection is of particular importance, since the immuno-
suppression used in the former can deteriorate liver dis-
ease in HCV patients, while interferon-alpha treatment
used in HCV infection may lead to exacerbation of AIH
[104,108-110].
The detection of non-organ specific autoantibodies
remains the hallmark of AIH. A step by step diagnostic
application of autoantibody tests is mandatory for the
evaluation of acute or chronic hepatitis of unknown
cause. ANA, SMA and anti-LKM-1 autoantibodies should
be first tested in patients with acute or chronic elevation
of aminotransferases when virologic tests are negative and
there is no current or past history for drug or alcohol
abuse. Determination of ANCA, which occur in up to 90%
of patients with AIH-1, may be useful in the identification
of individuals who are seronegative for the above conven-
tional autoantibody markers but should be kept in mind
that this autoantibody lacks specificity. Many target
autoantigens of the non-organ specific autoantibodies
have been identified, but the latter has not led to the
characterization of specific subpopulations of patients or
changes in the treatment strategies. In addition, most of
the non-organ specific autoantibodies do not seem to be
involved in the pathogenesis of liver injury in AIH. Anti-
LKM-1 autoantibodies could be an exception to the above
aspect since recent data have demonstrated the expression
of CYP2D6 on the surface of hepatocytes, while AIH-2 has
not been observed in individuals who are deficient for
CYP2D6. These findings provide arguments for an anti-
gen-driven autoimmune process. It is possible that muta-
tions in the autoantigen itself can lead to alterations in the
three dimensional structure of the antigen, which induces
autoimmunity.
Antibodies directed against liver-related antigens have
had similar limitations. Anti-ASGP-R and anti-LC1
autoantibodies appear to correlate with disease severity
and response to treatment suggesting a pathogenetic role
to the hepatocellular damage. In general however, autoan-
tibodies should not be used as a tool for monitoring of
treatment or to predict AIH activity and outcome. Anti-
SLA/LP autoantibodies have been considered as valuable
and specific markers for the diagnosis of AIH-1. However,
a recent study has shown that anti-SLA/LP autoantibodies
can also be detected in AIH-2 and in children with PSC.
Irrespective of the disease specificity of this marker, it is
obvious that testing for anti-SLA/LP will help to reduce
the group of cryptogenic liver disease, by recognizing pre-
viously misdiagnosed patients with AIH who were seron-
egative for ANA, SMA or anti-LKM-1.
In APECED, autoantibodies are directed against specific
cytochrome P450 enzymes (e.g. CYP1A2, CYP2A6,
CYP21, CYP17, and CYP11A1), that are expressed in
organs affected by the disease process. These observations
argue against the idea that antibodies against cytochrome
P450 complex are simply epiphenomena secondary to tis-
sue damage and that they have no relation to the etiology
and pathogenesis of APECED.
It is not known what triggers autoimmunity in AIH. The
hypothesis that different causes may lead to loss of toler-
ance against the same molecular target autoantigen seems
attractive. For instance, CYP1A2 is the molecular target in
dihydralazine-induced hepatitis and AIH as a component
of APECED, CYP2D6 in AIH-2 and in some patients with
HCV infection, CYP2A6 in APECED and in a proportion
of patients with HCV infection and UGT1 in some cases of
AIH-2 and chronic hepatitis D or C.
Research protocols in order to define AIH pathogenesis,
disease susceptibility, determinants of disease severity,
and to understand the epidemiology of AIH are future
Table 6: Differential Diagnosis of Autoimmune Hepatitis.
Other autoimmune liver diseases
- Overlap syndromes
- Primary biliary cirrhosis
- Primary sclerosing cholangitis
Chronic viral hepatitis
- Chronic hepatitis B with or without hepatitis delta
- Chronic hepatitis C
- Chronic hepatitis non A to G
Cholangiopathy due to human immunodeficiency virus infection
Alcoholic liver disease
Drug-induced hepatitis
Non-alcoholic steatohepatitis
Granulomatous hepatitis
Hemochromatosis
α1-antithrypsin deficiency
Wilson's disease
Systemic lupus erythematosusJournal of Autoimmune Diseases 2004, 1:2 http://www.jautoimdis.com/content/1/1/2
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challenges in the investigational and clinical arena of this
disease [139-141].
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